Rossari Biotech (ROSSARI) Aktievy
Rossari Biotech Limited är verksamt inom tillverkning och försäljning av specialkemikalier i Indien och internationellt. Mer information
| Snöflinga Score | |
|---|---|
| Värdering | 5/6 |
| Framtida tillväxt | 1/6 |
| Tidigare resultat | 3/6 |
| Finansiell hälsa | 4/6 |
| Utdelningar | 0/6 |
Belöningar
Riskanalys
Inga risker upptäckta för ROSSARI från våra riskkontroller.
ROSSARI Community Fair Values
Create NarrativeSee what 8 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Rossari Biotech Limited Konkurrenter
Prishistorik och prestanda
| Historiska aktiekurser | |
|---|---|
| Aktuell aktiekurs | ₹525.95 |
| 52 veckors högsta | ₹690.30 |
| 52 veckors lägsta | ₹375.00 |
| Beta | 0.55 |
| 1 månads förändring | 1.84% |
| 3 månaders förändring | -3.32% |
| 1 års förändring | -19.99% |
| 3 års förändring | -38.44% |
| 5 års förändring | -61.44% |
| Förändring sedan börsintroduktionen | -29.08% |
Senaste nyheter och uppdateringar
Uppdatering av berättelse • Jun 30
ROSSARI: New R&D Relocation Will Support Stronger Long-Term Prospects
Analysts have reduced their fair value estimate for Rossari Biotech from ₹813 to ₹637. This change reflects an updated view that combines a slightly lower discount rate and higher projected revenue growth with expectations of a lower profit margin and a reduced future P/E multiple.
Uppdatering av berättelse • Jun 16
ROSSARI: Navi Mumbai R And D Shift Will Drive Future Upside
Analysts have kept Rossari Biotech's fair value estimate steady at ₹601.75, with only minor adjustments to assumptions around the discount rate, revenue growth, profit margin and future P/E that do not materially change their overall valuation view. What's in the News Board meeting scheduled for May 27, 2026, at 16:00 IST to consider the re appointment of Ms. Esha Padmanabhan Achan as a Non Executive Independent Director and the grant of options under the Rossari Employee Stock Option Plan 2019.Uppdatering av berättelse • Jun 01
ROSSARI: New Navi Mumbai R And D Move Will Support Future Upside
Analysts have maintained their fair value estimate for Rossari Biotech at ₹601.75, with only minor adjustments to inputs such as the discount rate, revenue growth, profit margin, and future P/E assumptions, resulting in an unchanged price target. What's in the News A board meeting is scheduled for May 27, 2026 at 16:00 IST to consider the reappointment of Ms. Esha Padmanabhan Achan as a non-executive independent director and to evaluate the grant of options under the Rossari Employee Stock Option Plan 2019.Recent updates
Uppdatering av berättelse • Jun 30
ROSSARI: New R&D Relocation Will Support Stronger Long-Term Prospects
Analysts have reduced their fair value estimate for Rossari Biotech from ₹813 to ₹637. This change reflects an updated view that combines a slightly lower discount rate and higher projected revenue growth with expectations of a lower profit margin and a reduced future P/E multiple.Uppdatering av berättelse • Jun 16
ROSSARI: Navi Mumbai R And D Shift Will Drive Future Upside
Analysts have kept Rossari Biotech's fair value estimate steady at ₹601.75, with only minor adjustments to assumptions around the discount rate, revenue growth, profit margin and future P/E that do not materially change their overall valuation view. What's in the News Board meeting scheduled for May 27, 2026, at 16:00 IST to consider the re appointment of Ms. Esha Padmanabhan Achan as a Non Executive Independent Director and the grant of options under the Rossari Employee Stock Option Plan 2019.Uppdatering av berättelse • Jun 01
ROSSARI: New Navi Mumbai R And D Move Will Support Future Upside
Analysts have maintained their fair value estimate for Rossari Biotech at ₹601.75, with only minor adjustments to inputs such as the discount rate, revenue growth, profit margin, and future P/E assumptions, resulting in an unchanged price target. What's in the News A board meeting is scheduled for May 27, 2026 at 16:00 IST to consider the reappointment of Ms. Esha Padmanabhan Achan as a non-executive independent director and to evaluate the grant of options under the Rossari Employee Stock Option Plan 2019.Uppdatering av berättelse • May 14
ROSSARI: New R&D Consolidation And Board Decisions Will Drive Future Upside
Analysts now set a revised price target for Rossari Biotech at ₹601.75, down from ₹635.50, reflecting slightly softer assumptions around revenue growth, profit margins, and future P/E multiples. What's in the News Rossari Biotech has set up a new Research and Development Facility at Ellora Olearise, A-786, 06th Floor, Khairane MIDC, Koparkhairane, Navi Mumbai 400 710.Analysartikel • May 04
Rossari Biotech's (NSE:ROSSARI) Profits Appear To Have Quality Issues
Rossari Biotech Limited's ( NSE:ROSSARI ) stock didn't jump after it announced some healthy earnings. We did some...Uppdatering av berättelse • Apr 25
ROSSARI: Upcoming Board Meeting And Dividend Decision Will Shape Future Upside Potential
Analysts have kept Rossari Biotech's fair value estimate steady at ₹635.5, with only small technical tweaks to the discount rate, revenue growth, profit margin and future P/E assumptions, so the headline price target remains unchanged. What's in the News Board meeting scheduled for April 27, 2026, to review and approve audited standalone and consolidated financial statements for the quarter and financial year ended March 31, 2026 (company filing).Uppdatering av berättelse • Apr 09
ROSSARI: Greenfield Expansion And Subsidiary Restructuring Will Shape Future Upside Potential
Analysts have kept Rossari Biotech's fair value estimate steady at ₹635.50, citing only marginal tweaks to the discount rate, revenue growth, profit margin and future P/E assumptions rather than any major shift in the core outlook. What's in the News A board meeting is scheduled on January 17, 2026 at 12:30 Indian Standard Time to review unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025 (Key Developments).Uppdatering av berättelse • Mar 26
ROSSARI: Greenfield Capacity Expansion Will Support Future Upside Potential
Analysts have maintained the fair value estimate for Rossari Biotech at ₹635.5, making only minor technical adjustments to assumptions such as the discount rate, revenue growth, profit margin, and future P/E, which result in an essentially unchanged price target view. What's in the News A board meeting is scheduled for January 17, 2026, at 12:30 Indian Standard Time to review unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025 (company filing).Uppdatering av berättelse • Mar 08
ROSSARI: Greenfield Expansion And Subsidiary Buildout Will Support Future Upside
Analysts have maintained Rossari Biotech's fair value estimate at ₹635.50, making only minor adjustments to inputs such as the discount rate, revenue growth, profit margin and future P/E to reflect updated modelling assumptions rather than a change in conviction. What's in the News A board meeting is scheduled on Jan 17, 2026 at 12:30 Indian Standard Time to consider unaudited standalone and consolidated financial results for the quarter and nine months ended Dec 31, 2025 (company filing).Uppdatering av berättelse • Feb 22
ROSSARI: Greenfield Capacity Expansion Will Support Future Upside Potential
Analysts have kept their fair value estimate for Rossari Biotech steady at ₹635.5, with the unchanged price target reflecting only marginal tweaks to inputs such as discount rate, revenue growth, profit margin and future P/E assumptions. What's in the News Board meeting scheduled for January 17, 2026, to review unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025, and to consider several key corporate actions, including new projects and asset changes (company filing).Uppdatering av berättelse • Feb 05
ROSSARI: Greenfield Expansion And Subsidiary Reshaping Will Support Future Upside Potential
Analysts have trimmed their fair value estimate for Rossari Biotech slightly from ₹637.33 to ₹635.50, reflecting updated assumptions around discount rate, profit margin and future P/E, while keeping revenue growth expectations broadly aligned with prior views. What's in the News Board meeting scheduled on Jan 17, 2026 at 12:30 IST to review unaudited standalone and consolidated financial results for the quarter and nine months ended Dec 31, 2025, and to consider several corporate actions (company filing).Uppdatering av berättelse • Jan 22
ROSSARI: International Capacity Expansion Plans Will Drive Future Upside Potential
Analysts have revised their price target on Rossari Biotech lower from ₹795.75 to about ₹637.33, citing updated assumptions on the discount rate, revenue growth, profit margins and future P/E as key drivers of the change. What's in the News A board meeting is scheduled on Jan 17, 2026, to review unaudited standalone and consolidated financial results for the quarter and nine months ended Dec 31, 2025 (company filing).Analysartikel • Jan 22
Analysts Have Lowered Expectations For Rossari Biotech Limited (NSE:ROSSARI) After Its Latest Results
Shareholders might have noticed that Rossari Biotech Limited ( NSE:ROSSARI ) filed its third-quarter result this time...Uppdatering av berättelse • Jan 08
ROSSARI: International Capacity Expansions Will Drive Future Upside Potential
Analysts have kept their fair value estimate for Rossari Biotech steady at ₹795.75, with only small tweaks to assumptions such as discount rate, revenue growth, profit margin and future P/E to better reflect current expectations. What's in the News A board meeting is scheduled on December 18, 2025 at 10:30 a.m. Indian Standard Time to consider and approve the incorporation of a wholly owned subsidiary in the Republic of Singapore (company filing).Uppdatering av berättelse • Dec 21
ROSSARI: Planned Singapore Subsidiary Will Drive Future International Expansion Upside
Analysts have reaffirmed their price target on Rossari Biotech at ₹795.75 per share, with only marginal tweaks to underlying assumptions such as discount rate, long term revenue growth, profit margin, and future P E multiple, reflecting a largely unchanged outlook on the company’s earnings trajectory and risk profile. What's in the News Board to meet on December 18, 2025, to consider incorporating a wholly owned subsidiary in the Republic of Singapore (Board Meeting) Successfully commissioned an additional 20,000 MTPA capacity at the Dahej facility, taking total installed capacity to 1,52,500 MTPA (Business Expansions) Commissioned 15,000 MTPA ethoxylation capacity at Unitop in Phase 1 of a 30,000 MTPA plan, with Phase 2 expected by the third quarter of fiscal 2026 (Business Expansions) Board approved an investment of up to USD 8 million in Rossari International Limited Company in Saudi Arabia to evaluate and assess expansion plans in international markets (Business Expansions) Board meeting scheduled on October 15, 2025, to approve unaudited financial results for the quarter and half year ended September 30, 2025 (Board Meeting) Valuation Changes The consensus analyst price target remains unchanged at ₹795.75 per share, indicating a stable fair value assessment.Uppdatering av berättelse • Dec 06
ROSSARI: Capacity Expansion And Saudi Subsidiary Investment Will Drive Future Upside
Narrative Update on Rossari Biotech Analysts have maintained their price target for Rossari Biotech at ₹795.75, citing largely unchanged assumptions around discount rate, revenue growth, profit margins, and future valuation multiples. Taken together, these factors suggest limited change in the company’s fundamental outlook.Uppdatering av berättelse • Nov 22
ROSSARI: Additional Capacity Expansions Will Unlock Global Opportunities Ahead
Narrative Update on Rossari Biotech Analysts have maintained their fair value estimate for Rossari Biotech at ₹795.75, citing minimal changes in key financial assumptions and continued confidence in the company’s outlook. What's in the News Successfully commissioned an additional 20,000 MTPA capacity at the Dahej facility during the quarter, bringing total installed capacity to 1,52,500 MTPA.Uppdatering av berättelse • Nov 04
ROSSARI: New Expansion Projects Will Drive Global Market Penetration
Narrative Update on Rossari Biotech: Analyst Price Target Revision Analysts have revised Rossari Biotech’s fair value estimate downward from ₹826.67 to ₹795.75, citing slightly lower expectations for revenue growth and profit margins. What's in the News The company commissioned an additional 20,000 MTPA capacity at its Dahej facility, bringing total installed capacity to 1,52,500 MTPA (Key Developments).Analysartikel • Oct 28
We Think That There Are More Issues For Rossari Biotech (NSE:ROSSARI) Than Just Sluggish Earnings
Rossari Biotech Limited's ( NSE:ROSSARI ) recent weak earnings report didn't cause a big stock movement. Our analysis...Analysartikel • Jun 24
Here's Why Rossari Biotech Limited's (NSE:ROSSARI) CEO Compensation Is The Least Of Shareholders Concerns
Key Insights Rossari Biotech will host its Annual General Meeting on 30th of June Total pay for CEO Sunil Chari...
Ny berättelse • Feb 10
Eco-friendly Solutions And New Capacities Will Strengthen Future Prospects
Strategic investments in capacity expansion and innovation in eco-friendly solutions are expected to drive revenue growth in domestic and international markets.Analysartikel • Aug 17
Why We Think Rossari Biotech Limited's (NSE:ROSSARI) CEO Compensation Is Not Excessive At All
Key Insights Rossari Biotech's Annual General Meeting to take place on 23rd of August Salary of ₹12.1m is part of CEO...Analysartikel • Jun 14
Is Rossari Biotech (NSE:ROSSARI) Using Too Much Debt?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Analysartikel • May 07
Rossari Biotech's (NSE:ROSSARI) Solid Profits Have Weak Fundamentals
Investors were disappointed with Rossari Biotech Limited's ( NSE:ROSSARI ) earnings, despite the strong profit numbers...Analysartikel • May 03
Analyst Estimates: Here's What Brokers Think Of Rossari Biotech Limited (NSE:ROSSARI) After Its Annual Report
Last week, you might have seen that Rossari Biotech Limited ( NSE:ROSSARI ) released its full-year result to the...Analysartikel • Feb 10
One Analyst Just Shaved Their Rossari Biotech Limited (NSE:ROSSARI) Forecasts Dramatically
The analyst covering Rossari Biotech Limited ( NSE:ROSSARI ) delivered a dose of negativity to shareholders today, by...Analysartikel • Sep 23
Returns On Capital At Rossari Biotech (NSE:ROSSARI) Paint A Concerning Picture
What trends should we look for it we want to identify stocks that can multiply in value over the long term? In a...Analysartikel • Apr 06
Returns On Capital Signal Tricky Times Ahead For Rossari Biotech (NSE:ROSSARI)
Finding a business that has the potential to grow substantially is not easy, but it is possible if we look at a few key...Analysartikel • Feb 19
Need To Know: Analysts Are Much More Bullish On Rossari Biotech Limited (NSE:ROSSARI) Revenues
Rossari Biotech Limited ( NSE:ROSSARI ) shareholders will have a reason to smile today, with the analysts making...Analysartikel • Feb 17
Rossari Biotech Limited Just Beat Revenue Estimates By 6.8%
Shareholders might have noticed that Rossari Biotech Limited ( NSE:ROSSARI ) filed its third-quarter result this time...Analysartikel • Feb 10
I Ran A Stock Scan For Earnings Growth And Rossari Biotech (NSE:ROSSARI) Passed With Ease
Some have more dollars than sense, they say, so even companies that have no revenue, no profit, and a record of falling...Analysartikel • Nov 24
Capital Allocation Trends At Rossari Biotech (NSE:ROSSARI) Aren't Ideal
If we want to find a stock that could multiply over the long term, what are the underlying trends we should look for...Analysartikel • Oct 12
With EPS Growth And More, Rossari Biotech (NSE:ROSSARI) Is Interesting
Some have more dollars than sense, they say, so even companies that have no revenue, no profit, and a record of falling...Aktieägarnas avkastning
| ROSSARI | IN Chemicals | IN Marknad | |
|---|---|---|---|
| 7D | 3.6% | 1.1% | 1.6% |
| 1Y | -20.0% | -1.0% | 4.8% |
Avkastning vs industri: ROSSARI presterade sämre än Indian Chemicals branschen som gav -1 % under det senaste året.
Avkastning vs Marknaden: ROSSARI presterade sämre än Indian marknaden som gav 4.8 % under det senaste året.
Prisvolatilitet
| ROSSARI volatility | |
|---|---|
| ROSSARI Average Weekly Movement | 5.8% |
| Chemicals Industry Average Movement | 6.0% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in IN Market | 9.1% |
| 10% least volatile stocks in IN Market | 3.7% |
Stabil aktiekurs: ROSSARI har inte haft någon betydande prisvolatilitet under de senaste 3 månaderna jämfört med marknaden för Indian.
Volatilitet över tid: ROSSARI s veckovolatilitet ( 6% ) har varit stabil under det senaste året.
Om företaget
| Grundad | Anställda | VD OCH KONCERNCHEF | Webbplats |
|---|---|---|---|
| 1997 | 585 | Sunil Chari | www.rossari.com |
Rossari Biotech Limited är verksamt inom tillverkning och försäljning av specialkemikalier i Indien och internationellt. Företaget erbjuder tvål och rengöringsmedel, bläck, färger och ytbeläggningar, keramik och kakel, massa och papper, cement, tillsatser och lösningar för vattenrening. Företaget tillhandahåller också specialkemikalier för textil, t.ex. bomull, polyester, akryl, ull, silke, nylon, funktionella ytbehandlingar, denim, tryck och hållbara lösningar, samt skötselprodukter för husdjur, som omfattar naturliga schampon, pulver, deodoranter, sprayer, krämer och golvtvättvätskor under varumärkena Lozalo, Hunger Fills och Sniffy.
Rossari Biotech Limited Sammanfattning av grunderna
| ROSSARI grundläggande statistik | |
|---|---|
| Börsvärde | ₹29.08b |
| Vinst(TTM) | ₹1.51b |
| Intäkter(TTM) | ₹25.50b |
19.3x
P/E-förhållande1.1x
P/S-förhållandeÄr ROSSARI övervärderat?
Se Verkligt värde och värderingsanalysResultat & intäkter
| ROSSARI resultaträkning (TTM) | |
|---|---|
| Intäkter | ₹25.50b |
| Kostnad för intäkter | ₹17.97b |
| Bruttovinst | ₹7.53b |
| Övriga kostnader | ₹6.02b |
| Intäkter | ₹1.51b |
Senast redovisade vinst
Jun 30, 2026
Nästa vinstdatum
n/a
| Vinst per aktie (EPS) | 27.21 |
| Bruttomarginal | 29.53% |
| Nettovinstmarginal | 5.91% |
| Skuld/egenkapitalförhållande | 32.7% |
Hur har ROSSARI utvecklats på lång sikt?
Se historisk utveckling och jämförelseUtdelningar
0.1%
Aktuell utdelningsavkastning2%
UtbetalningskvotGer ROSSARI en tillförlitlig utdelning?
Se ROSSARI utdelningshistorik och jämförelsetal| Rossari Biotech datum för utdelning | |
|---|---|
| Ex utdelningsdag | Jul 10 2026 |
| Utbetalningsdag för utdelning | Aug 19 2026 |
| Dagar till Ex-utdelning | 28 days |
| Dagar till utdelningsdag | 12 days |
Ger ROSSARI en tillförlitlig utdelning?
Se ROSSARI utdelningshistorik och jämförelsetalFöretagsanalys och finansiella data Status
| Uppgifter | Senast uppdaterad (UTC-tid) |
|---|---|
| Analys av företag | 2026/08/06 13:06 |
| Aktiekurs vid dagens slut | 2026/08/06 00:00 |
| Intäkter | 2026/06/30 |
| Årlig intjäning | 2026/03/31 |
Datakällor
Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.
| Paket | Uppgifter | Tidsram | Exempel US-källa |
|---|---|---|---|
| Företagets finansiella ställning | 10 år |
| |
| Analytikernas konsensusuppskattningar | +3 år |
|
|
| Marknadspriser | 30 år |
| |
| Ägarskap | 10 år |
| |
| Förvaltning | 10 år |
| |
| Viktiga utvecklingstendenser | 10 år |
|
* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.
Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.
Analysmodell och snöflinga
Detaljer om analysmodellen som används för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och handledningar på Youtube.
Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.
Industri- och sektormått
Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.
Källor för analytiker
Rossari Biotech Limited bevakas av 5 analytiker. 4 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.
| Analytiker | Institution |
|---|---|
| null null | Anand Rathi Shares and Stock Brokers Limited |
| Nitesh Dhoot | Anand Rathi Shares and Stock Brokers Limited |
| Abhishek Navalgund | Centrum Broking Limited |